Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone

Supportive Care in Cancer

Volumn 21, Issue 10, 2013, Pages 2783-2791

  Lanzarotti, Corinna ^a   Rossi, Giorgia ^a  

^a HELSINN HEALTHCARE SA   (Switzerland)

Author keywords

CYP3A4 substrates; Dexamethasone; Drug drug interaction; Erythromycin; Midazolam; Netupitant

Indexed keywords

DEXAMETHASONE; ERYTHROMYCIN; MIDAZOLAM; NETUPITANT;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG FATALITY; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFECTION; INSOMNIA; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; NEUROKININ-1 RECEPTOR ANTAGONISTS; PYRIDINES; YOUNG ADULT;

EID: 84884282323     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1855-y     Document Type: Article

References (31)

1. Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30-38
2. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bever MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-227
3. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074-1080
4. Roila F, Herrstedt J, Aapro M, Gralla RJ, et al. (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. www.mascc.org. Annals of Oncology 21 (Supplement 5): v232-v243
5. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, et al. (2012) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. www.asco.org. J Clin Oncol 29(31):4189-4198
6. NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1. (2012) www.nccn.org
7. Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo' G (2010) In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist, netupitant. Peptides 37(1):86-97
8. Rojas C, Slusher BS (2012) Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 5;684(1-3):1-7. Epub 2012 Mar 9
9. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570-1577
10. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473-2482
11. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441-1449
12. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115-124, Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 11(3)226
13. Giuliano C, Calcagnile S, Mair S, Stevens L, Nisbet I (2012) ADME study of 14(C) netupitant administered as an oral 300 mg suspension to healthy male subjects. Ann Oncol 23(Supplement 9):ix499-ix527. doi: 10.1093/annonc/mds416, abstract 1575P
14. Aloxi (2013) [package insert] HELSINN, Manufactured for Helsinn Healthcare SA, Switzerland, Distributed and marketed by Eisai, Inc.
15. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when co-administered with ketoconazole, rifampicin and oral contraceptives (accepted for publication in the present issue)
16. Giuliano C, Lovati E, Funk C, Potthast M, Pietra C (2012) In vitro drug-drug interaction studies with the antiemetic drug Netupitant and its major metabolites (M1 and M2), involving main human cytochrome P450 isoenzymes. Ann Oncol 23(Supplement 9):ix499-ix527. doi: 10.1093/annonc/mds416, (abstract 1618)
17. Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21(12):2316-2323
18. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group, FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815-832
19. Zamuner S, Johnson BM, Pagliarusco S, Fina P, Peroni M, Fiore M, Adams LM, Fernandes SA (2010) Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. Br J Clin Pharmacol 70(4):537-546
20. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74(2):150-156
21. Marbury TC, Ngo PL, Shadle CR, Jin B, Panebianco D, Caro L, Valentine J, Murphy G (2011) Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 51(12):1712-1720
22. Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE (2007) Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol 47(6):744-750
23. Stoch SA, Gargano C, Valentine J, Braun MP, Murphy MG, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Kraft WK, Greenberg HE (2011) Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol 67(6):1313-1321
24. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44(3):215-223
25. EMEND (2013) [package insert], Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA
26. Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 17(9):1177-1185
27. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, Murphy MG, Gottesdiener KM, Goldwater DR, Blum RA (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74(1):17-24
28. Chawla SP, Grunberg SM, Gralla RJ et al (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300
29. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083-1088. doi: 10.1093/annonc/mdp584, Epub 2010 Jan 15
30. Celio L, Denaro A, Agustoni F, Bajetta E (2012) Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol 10(2):65-71
31. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5):589-594